On October 13, 2025 Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, reported that the company and its research collaborators will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2025 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress from October 17-21 in Berlin, Germany (Press release, Foundation Medicine, OCT 13, 2025, View Source [SID1234656604]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Foundation Medicine’s research to be presented at the meeting spans seven disease areas and includes new insights from the company’s tissue-free monitoring assay FoundationOneMonitor, which will soon be available for clinical use. The abstract showcases that an early reduction of circulating tumor DNA using FoundationOne Monitor was associated with improved outcomes in patients with triple negative breast cancer.

Two additional studies spotlight data from FoundationOneRNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. Respectively, the results demonstrate the test’s strong concordance with results from the company’s FDA-approved tissue-based comprehensive genomic profiling test, FoundationOneCDx, as well as with IHC/FISH tests.

"At this year’s ESMO (Free ESMO Whitepaper) Congress, we’re looking forward to sharing our latest data which reinforces the value of our high-quality tests to support the best precision care for patients," says Foundation Medicine’s Vice President, Head of Clinical Development, Amaya Gascó, M.D., Ph.D. "In particular, a new study using FoundationOne Monitor demonstrates the test’s ability to inform a patient’s response to treatment and guide next steps in care. Additionally, our FoundationOne RNA studies highlight the powerful insights our RNA sequencing test can deliver as a complement to comprehensive genomic sequencing with FoundationOneCDx and other diagnostic tests, such as IHC/FISH, to provide healthcare providers with the confidence they need to make informed decisions for their patients."

To access all the abstracts being presented at the 2025 ESMO (Free ESMO Whitepaper) Congress, please visit ESMO (Free ESMO Whitepaper).com.

Follow Foundation Medicine on LinkedIn, X, Instagram and Bluesky for more updates from #ESMO25, and join us in person at Booth #3028 in Hall 3.2 for our "Booth Talk Series" where you will hear from our team of experts on the latest advancements that are driving innovation in precision diagnostics.

Complete list of Foundation Medicine’s abstracts at the 2025 ESMO (Free ESMO Whitepaper) Congress

Presentation Number

Title

Product

Saturday, October 18

Oral Presentation

2610MO

Genomic analysis of papillary renal cell carcinoma (PRCC): MET alterations are uncommon and enriched in patients of African ancestry

FoundationOneCDx

Poster Presentations

1146P

Genomic landscape of HRD signature (HRDsig), CCNE1 amplified (amp) and ERBB2 altered (alt) ovarian cancers (OC)

FoundationOneCDx

1936P

Genomic alterations (GA) in TP53 including the targetable TP53 Y220C mutation in clinically advanced non-small cell lung cancer (CANSCLC)

FoundationOneCDx

157P

Homologous recombination signature (HRDsig) in non-small cell lung cancer (NSCLC): Implications for PARP inhibitor (PARPi) treatment

FoundationOneCDx

1931P

Prevalence, co-alterations and preclinical characterization of FGFR variants of unknown significance in non-small cell lung cancer

FoundationOneCDx

Sunday, October 19

2150P

Homologous recombination deficiency signature in gastric adenocarcinoma

FoundationOneCDx

Monday, October 20

579P

Gene expression profiling by RNA sequencing accurately predicts estrogen, progesterone, and HER2 receptor status by immunohistochemistry in breast cancer

FoundationOneCDx, FoundationOneRNA

580P

Androgen receptor splice variant 7 (AR-V7) and ESR1 fusion detection in breast cancer utilizing comprehensive combined DNA and RNA sequencing

FoundationOneCDx, FoundationOneRNA

2697P

Comprehensive genomic profiling in chordoma by subtype classification

FoundationOneHeme, FoundationOne, FoundationOneCDx

2701P

Estrogen receptor and AKT pathways as potential novel targets for MDM2-amplified well-differentiated and dedifferentiated liposarcoma (WD/DD LPS)

FoundationOneHeme, FoundationOne, FoundationOneCDx

558P

Circulating tumor DNA dynamics correlate with response to carboplatin with or without nivolumab in metastatic TNBC

FoundationOneMonitor

Published Online

2525eP

RNA sequencing enhances TMPRSS2 fusion detection beyond DNA sequencing alone and reveals associations with androgen receptor (AR) biology in prostate cancer

FoundationOneCDx, FoundationOneRNA

1458eP

Ameloblastoma of the head and neck (HNAmelo): A biomarker and genomic landscape study

FoundationOneCDx

686eP

Clinical utility of DNA and RNA comprehensive genomic profiling (CGP) for the diagnostic workup of high grade gliomas (HGG)

FoundationOneCDx, FoundationOneRNA